Pembrolizumab (Keytruda): A Breakthrough in Cancer Immunotherapy

What Is Pembrolizumab?

Pembrolizumab, marketed under the brand name Keytruda, is a groundbreaking immunotherapy drug developed by Merck & Co. It has transformed the landscape of oncology by introducing a novel way to treat cancer — not by targeting cancer cells directly, but by unleashing the body’s immune system to do the work. This medication belongs to a class known as immune checkpoint inhibitors, which work by targeting the PD-1 (programmed death-1) receptor pathway.

Cancer cells often evade immune detection by exploiting the PD-1/PD-L1 pathway, essentially signaling the immune system to ignore them. Pembrolizumab binds to PD-1 receptors on T-cells and blocks this interaction, restoring the ability of immune cells to detect and destroy cancerous cells. This allows for a more targeted, sustained, and sometimes more tolerable form of therapy compared to traditional options like chemotherapy and radiation.

Medical Uses of Pembrolizumab

Pembrolizumab is approved for a wide range of cancers and is considered a first-line treatment in many cases, especially when tumors express high levels of PD-L1. Here’s a breakdown of cancers where pembrolizumab has shown significant benefits:

1. Non-Small Cell Lung Cancer (NSCLC)

NSCLC is one of the most common and deadly cancers worldwide. Pembrolizumab is used as:

• First-line monotherapy in patients with metastatic NSCLC with PD-L1 expression ≥50%.
• In combination with chemotherapy for patients regardless of PD-L1 status.
• Maintenance therapy following initial chemotherapy.

Clinical trials have shown that pembrolizumab can improve overall survival and reduce tumor progression significantly compared to chemotherapy alone.

2. Melanoma

For patients with unresectable or metastatic melanoma, pembrolizumab provides a strong alternative to traditional therapies. It has demonstrated durable responses and is often used:

• As a monotherapy in advanced stages.
• In adjuvant settings post-surgery to prevent recurrence.
• In combination with other immunotherapies for resistant tumors.

3. Head and Neck Squamous Cell Carcinoma (HNSCC)

Pembrolizumab is used in patients with recurrent or metastatic HNSCC, particularly if the tumor expresses PD-L1 (CPS ≥1). It offers an overall survival advantage, especially in previously treated individuals who have failed platinum-based therapies.

4. Classical Hodgkin Lymphoma (cHL)

This is one of the few hematologic malignancies where pembrolizumab is approved. It is particularly effective for:

• Adult and pediatric patients with relapsed/refractory cHL.
• Those who have failed stem cell transplant or Brentuximab vedotin.

5. Urothelial Carcinoma (Bladder Cancer)

Approved for patients who:

• Are ineligible for cisplatin chemotherapy.
• Have progressed after platinum-containing therapy.
• Exhibit high PD-L1 expression.

6. Triple-Negative Breast Cancer (TNBC)

One of the most aggressive breast cancer subtypes, TNBC has limited treatment options. Pembrolizumab is approved in combination with chemotherapy for locally recurrent unresectable or metastatic TNBC with PD-L1 positivity (CPS ≥10).

7. Colorectal Cancer (MSI-H/dMMR)

Pembrolizumab offers a precision therapy approach for:

• Metastatic colorectal cancer with MSI-H (microsatellite instability-high) or dMMR (deficient mismatch repair).
• Patients who have failed conventional chemotherapies.

8. Gastric or Gastroesophageal Junction Adenocarcinoma

Used as a second-line or later therapy in tumors with PD-L1 CPS ≥1. Though not curative, it provides disease control and symptom relief in advanced stages.

9. Cervical Cancer

A vital option for women with recurrent or metastatic PD-L1-positive cervical cancer, pembrolizumab is typically administered after failure of first-line platinum-based therapy.

10. Endometrial Carcinoma

Pembrolizumab combined with lenvatinib is approved for advanced endometrial cancer in patients who are not candidates for curative surgery or radiation, regardless of biomarker status.

How Pembrolizumab Works

The immune system is normally able to distinguish self from non-self, but cancer cells have evolved mechanisms to suppress immune recognition. One such tactic involves the PD-1/PD-L1 pathway. Tumors often express PD-L1, a protein that binds to the PD-1 receptor on T-cells, effectively turning off the immune response.

Pembrolizumab is a monoclonal antibody that binds to the PD-1 receptor, blocking this interaction. As a result:

• T-cells are reactivated.
• Immune surveillance is restored.
• Tumor cells become vulnerable to immune attack.

This process can lead to tumor shrinkage, prolonged survival, and in some cases, complete remission.

Dosing Schedule and Administration

Pembrolizumab is administered as an intravenous (IV) infusion in a hospital or outpatient clinic setting.

Standard Dosing:

• 200 mg every 3 weeks, or
• 400 mg every 6 weeks

Infusions typically last 30 minutes. The total number of treatment cycles depends on:

• Type of cancer
• Patient response
• Tolerance to the drug

Many patients continue therapy for up to 2 years, especially if they maintain stable disease or show improvement.

Monitoring During Treatment:

• Blood tests to monitor liver, kidney, and thyroid function.
• Imaging scans (CT, MRI, or PET) every few months.
• Regular physical exams and side effect assessments.

Common and Serious Side Effects

Immune checkpoint inhibitors like pembrolizumab can cause immune-related adverse events (irAEs). While many patients tolerate the drug well, others may experience side effects due to increased immune activation.

Common Side Effects:

• Fatigue
• Rash and itching
• Nausea and vomiting
• Decreased appetite
• Joint pain (arthralgia)
• Shortness of breath

Serious (but rare) Immune-Mediated Reactions:

• Pneumonitis: inflammation of lung tissue, potentially life-threatening.
• Hepatitis: liver inflammation leading to elevated enzymes.
• Colitis: severe diarrhea and abdominal pain.
• Endocrinopathies: including hypothyroidism, adrenal insufficiency, or type 1 diabetes.
• Nephritis: inflammation of the kidneys that may require corticosteroids or hospitalization.

Most serious side effects are manageable with early detection and treatment using corticosteroids or immune suppression.

Pembrolizumab Cost and Pricing

The financial cost of pembrolizumab is a significant concern, particularly in countries without comprehensive healthcare systems.

U.S. Market Pricing:

• Each dose (200 mg) may cost between $9,000 to $12,000.
• Total annual treatment costs can surpass $150,000–$200,000.

Global Pricing Variations:

• India: Pembrolizumab is available at a significantly lower cost, ranging from INR 1.5 lakh to 3 lakh per dose.
• Europe and Canada: Covered under national health systems, often reducing out-of-pocket expenses.

Financial Support Programs:

• Merck Access Program: Offers assistance for eligible U.S. patients.
• Private Insurance and Copay Cards: May cover full or partial costs.
• Nonprofits and NGOs: May offer help with funding or sourcing medication abroad.

What to Expect During Treatment

Understanding what to expect can empower patients and reduce treatment-related anxiety.

Pre-Treatment:

• Consultation with oncologist and immunotherapy specialist.
• Blood tests and PD-L1 biomarker testing.
• Review of previous treatment history.

During Infusion:

• IV line inserted in the arm or hand.
• Infusion over 30 minutes.
• Post-infusion monitoring for signs of allergic reactions or fatigue.

After Treatment:

• Most patients resume normal activities within 24 hours.
• Common advice includes staying hydrated, resting, and avoiding infection.
• Regular follow-ups and imaging scans help track progress.

Real Patient Experiences:

Many individuals report feeling minimal side effects compared to chemotherapy. Patient testimonials often describe:

• Increased energy
• Emotional uplift from tumor regression
• Hope from long-term remission

However, others caution about unexpected immune flares and emphasize the importance of open communication with healthcare teams.

Is Pembrolizumab Right for You?

Pembrolizumab may be an appropriate option if:

• You have advanced-stage cancer with limited options.
• Your tumor expresses PD-L1, or shows MSI-H/dMMR status.
• You are eligible based on clinical guidelines and biomarker results.

Always discuss treatment risks and benefits with a board-certified oncologist. Personalized medicine and genomic profiling play an essential role in determining suitability.

---

Final Thoughts

Pembrolizumab (Keytruda) represents a revolution in cancer care. It moves beyond traditional treatments by engaging the body’s immune defense mechanisms. Although not a cure for all, it has provided hope to thousands worldwide, especially those with difficult-to-treat cancers.

Keytruda is a shining example of how immunotherapy can lead to durable responses, fewer side effects, and sometimes even complete remission. As ongoing research expands its indications, the future of pembrolizumab looks even more promising.

For those beginning this journey, education, support, and expert guidance make all the difference. Ask questions, understand your biomarkers, and never lose hope — because science and your body may be more powerful than you think.

---